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Small molecules targeted to the microtubule–Hec1 interaction
inhibit cancer cell growth through microtubule stabilization
M Ferrara1,4, G Sessa1,4, M Fiore1, F Bernard1, IA Asteriti1, E Cundari1, G Colotti1, S Ferla2, M Desideri3, S Buglioni3, D Trisciuoglio1,3,
D Del Bufalo3, A Brancale2 and F Degrassi1
Highly expressed in cancer protein 1 (Hec1) is a subunit of the kinetochore (KT)-associated Ndc80 complex, which ensures
proper segregation of sister chromatids at mitosis by mediating the interaction between KTs and microtubules (MTs). HEC1 mRNA
and protein are highly expressed in many malignancies as part of a signature of chromosome instability. These properties render
Hec1 a promising molecular target for developing therapeutic drugs that exert their anticancer activities by producing massive
chromosome aneuploidy. A virtual screening study aimed at identifying small molecules able to bind at the Hec1–MT interaction
domain identiﬁed one positive hit compound and two analogs of the hit with high cytotoxic, pro-apoptotic and anti-mitotic
activities. The most cytotoxic analog (SM15) was shown to produce chromosome segregation defects in cancer cells by inhibiting
the correction of erroneous KT–MT interactions. Live cell imaging of treated cells demonstrated that mitotic arrest and segregation
abnormalities lead to cell death through mitotic catastrophe and that cell death occurred also from interphase. Importantly, SM15
was shown to be more effective in inducing apoptotic cell death in cancer cells as compared to normal ones and effectively
reduced tumor growth in a mouse xenograft model. Mechanistically, cold-induced MT depolymerization experiments
demonstrated a hyper-stabilization of both mitotic and interphase MTs. Molecular dynamics simulations corroborate this ﬁnding by
showing that SM15 can bind the MT surface independently from Hec1 and acts as a stabilizer of both MTs and KT–MT interactions.
Overall, our studies represent a clear proof of principle that MT-Hec1-interacting compounds may represent novel powerful
anticancer agents.
Oncogene advance online publication, 18 September 2017; doi:10.1038/onc.2017.320
INTRODUCTION
Aneuploidy and chromosome instability are strongly involved in
tumorigenesis. However, studies on the cancer susceptibility of
mouse models heterozygous for genes controlling chromosome
segregation suggest that aneuploidy may also act as a tumor
suppressive mechanism, depending on the tissue analyzed and its
intrinsic chromosome instability.1,2 This evidence suggests that
excessive chromosome mis-segregation may compromise gen-
ome stability and be incompatible with cell viability. Concordantly,
partial downregulation of mitotic checkpoint proteins in tumor
cell lines produced cancer cell death associated with severe
chromosome mis-segregation.3 Moreover, overexpression of
cyclin E inducing multipolar divisions and numerous chromosome
segregation errors was found to have a signiﬁcant anti-
tumorigenic effect in a mouse model for lung cancer.4 Conse-
quently, the idea of promoting cell death by inducing massive
chromosome mis-segregation at mitotic division was proposed as
a therapeutic strategy to selectively eliminate actively proliferating
tumor cells.5
Highly expressed in cancer protein 1 (Hec1) is a subunit of the
kinetochore (KT)-associated Ndc80 complex, which mediates the
attachment of microtubules (MTs) to the KT during mitotic division
and ensures proper alignment and segregation of sister
chromatids.6,7 Moreover, HEC1 mRNA is highly expressed in many
malignancies and elevated Hec1 expression is associated with
negative prognosis in multiple cancer types.8–10 Therefore, Hec1
represents a promising molecular target for developing new
therapeutic drugs that exert their anticancer property by
producing massive chromosome aneuploidy and cell death in
cancer cells. We previously showed that expression of a Hec1
protein modiﬁed at its N-terminus, the region of interaction with
MTs, massively kills cancer cells both in vitro and in tumor
xenografts. Live cell imaging of N-terminus modiﬁed Hec1-
expressing cells demonstrated that cancer cell death is triggered
by a prolonged mitotic arrest owing to an attempted chromosome
segregation within multipolar spindles followed by cell death at
mitosis.11,12 These studies provided a clear proof of concept that
the KT protein Hec1 can be a good target for developing
anticancer therapies.
X-ray crystallographic studies have revealed that the N-terminal
globular head of the Hec1 protein directly binds the MT lattice
through a calponin homology domain.13,14 Structural reconstruc-
tions of Ndc80 complexes bound to MTs have further restricted
the region of interaction by identifying a region within the
calponin homology domain of Hec1 named ‘toe’ region that binds
a pocket on the MT present at both intra-dimer and inter-dimer
tubulin interfaces.15,16 In the ‘toe’ region positively charged amino
acid residues interact with negatively charged residues on the ‘toe
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print’ MT interface, and residues important for MT binding within
the ‘toe’ have also been identiﬁed.14,17,18 The ‘toe’–‘toe print’
interaction interface represents an ideal target for developing new
compounds that speciﬁcally inhibit/modify the MT-Hec1 interac-
tion and can potentially produce massive chromosome mis-
segregation and cancer cell death.
In this study, the SPECS library of commercially available
compounds was screened in silico aiming to ﬁnd small molecules
(SMs) able to bind at the interaction domain between MTs and
Hec1. The adopted approach has led to the identiﬁcation of a ﬁrst
hit compound and an analog of the initial hit with promising
anticancer properties.
RESULTS
Virtual screening
The Hec1 ‘toe’ region was demonstrated to bind the MT wall by
interacting with intra-dimer and inter-dimer tubulin interfaces.
Examining the model of the Ndc80 kinetochore complex (PDB
code 3IZ0), an interesting and well-deﬁned pocket was found at
the interface between the two tubulin subunits (Figure 1a).
Although this pocket seems not directly involved in the MT–Hec1
interaction, it is adjacent to the tubulin-Hec1 contact area and in
proximity of Lys166, which is thought to be part of a MT
conformation sensor.16 The selected pocket, deﬁned by Trp407
and Glu411 (α-tubulin chain) and Ile165, Asp163, Asp199 and
Arg253 (β-tubulin chain), was used to screen the SPECS library of
commercially available compounds (~350.000 SMs) aiming at
identifying chemical inhibitors/modulators of the MT–Hec1
interaction. A high-throughput virtual screening identiﬁed 15
SMs as potential inhibitors/modulators of MT–Hec1 interactions.
Among the 15 selected molecules, compound FB induced
alterations in the mitotic process and reduced cell viability in
HeLa cells (Supplementary Figure 1, IC50 = 20.18 μM). To explore
the structure-activity relationship and possibly increase the afﬁnity
for the target and the biological potency, several FB analogs were
selected and their IC50 was evaluated in dose–response experi-
ments in HeLa cells (Supplementary Figure 2). Among the FB
analogs, two compounds more cytotoxic than the lead compound
(SM15 and SM17: IC50 = 6.0 μM and 15.3 μM, respectively) and one
inactive compound (SM16: IC50 > 100 μM) were identiﬁed. The
structures of FB and its active analogs are reported in Figure 1b.
Time course experiments conﬁrmed IC50 studies by showing the
high potency of SM15 and SM17 in inhibiting cell proliferation
(Figure 1c). Cancer speciﬁcity of the most cytotoxic molecule SM15
was then investigated by extending the analysis to a non
Figure 1. A virtual screening targeted to the MT–Hec1 interaction identiﬁes highly cytotoxic compounds. (a) Crystal structure of the α (sky
blue) and β (pink) tubulin dimer in association with the Ndc80-SPC25 chimera protein (teal). The ‘toe’ region of Hec1 is in yellow. The zoom
highlights the pocket (represented as gray molecular surface) at the interface between the two tubulin monomers where the virtual screening
study has been performed. Important amino acid residues from α-tubulin chain and β-tubulin chain are reported. Hec1 Lys166 is in proximity
of the selected pocket. The protein backbone is shown as ribbon. (b) Chemical structure of FB and its derivatives SM15 and SM17. (c) Time
course viability assay for selected compounds (FB, SM15, SM16, SM17). Data are means± s.e.m. of 2–4 independent experiments. (d)
Sensorgrams showing the interaction between MTs, immobilized on a COOH5 chip, and SM15 at different concentrations. (e) Sensorgrams
showing the interaction between tubulin, immobilized on a COOH5 chip, and SM15 at different concentrations. Concentrations of SM15 were:
0.78 μM: cyan; 1.56 μM: black; 3.12 μM: red; 6.25 μM: blue; 12.5 μM: green; 25 μM: magenta. The increase in RU relative to baseline indicates
complex formation; the plateau region represents the steady-state phase of the interaction, whereas the decrease in RU represents
dissociation of SM15 from immobilized ligands after injection of running buffer. (f) Scatchard plots of SPR experiments showing the
interaction (that is, RU values at equilibrium) of SM15 at different concentrations with MTs (circles) and tubulin (squares). Upon linear ﬁtting,
KD values of 0.94± 0.13 μM and 1.8± 0.4 μM were calculated for the SM15 interaction with MTs and tubulin, respectively.
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tumorigenic mammary epithelial cell line (MCF10A cells) and to
breast cancer MDA-MB-231 cells. HeLa and MDA-MB-231 cells
were found more sensitive than MCF10A cells to the growth
inhibitory and cell killing effects of SM15 in the dose range of 1–
30 μM (Supplementary Figure 3), demonstrating that SM15 is a
stronger inducer of cell death in cancer cells as compared with
normal ones.
To support the assumption that the analogs directly interact
with MTs, SM15 was subjected to surface plasmon resonance
(SPR), which allows the evaluation of kinetics and afﬁnity of the
binding between proteins and SMs. SPR experiments showed that
SM15 interacts directly and with high afﬁnity with both assembled
MTs (Figure 1d) and dimeric tubulin (Figure 1e). Scatchard plots of
SPR experiments showed that SM15 binds to MTs with a higher
afﬁnity with respect to tubulin dimers (KD = 0.94 ± 0.1 μM and
1.80 ± 0.4 μM, respectively; Figure 1f).
Cell cycle arrest and apoptosis
To characterize the cell death pathway activated by the SMs we
evaluated cell cycle distribution in HeLa cells by ﬂow cytometry.
SM15 treatment arrested HeLa cells in the G2/M phases of the cell
cycle more efﬁciently than FB (Figures 2a and b) and signiﬁcantly
enhanced the percentage of hypodiploid apoptotic cells
(Figures 2c and d). A strong accumulation of cells in the G2/M
phases was associated with an increment in polyploid cells for
24 h treatments. This was followed by a massive induction of
hypodiploid cells at later times (Figures 2b and d and
Supplementary Figure 4). These ﬁndings conﬁrmed the cytotoxic
potential of both analogs and suggested that cell death was
dependent on the G2/M arrest, presumably a mitotic arrest.
Induction of apoptosis was conﬁrmed by the cleavage of the
apoptotic marker poly ADP-ribose polymerase, by caspase 3
activation and by the reduction in DNA fragmentation observed in
the presence of the pan-caspase inhibitor Z-VAD-fmk in both HeLa
and MDA-MB-231 cells (Figure 2e, Supplementary Figure 5).
Analysis of mitosis
Next, we sought to further investigate the possible mechanisms
responsible for the observed cytotoxic effects. As cells defective
for Hec1 function show chromosome segregation and spindle
abnormalities,6,17–19 we analyzed the mitotic phenotypes of SM-
treated HeLa cells. Mitotic progression from metaphase to
anaphase was clearly inhibited after 3 h exposure to SM15,
SM17 or FB (Figure 3a), suggesting activation of the spindle
assembly checkpoint. Unattached or faulty attached KTs activate
spindle assembly checkpoint that delays mitotic progression into
anaphase until sister KTs attach properly to spindle MTs and
chromosomes congress to the metaphase plate.20,21 We then
analyzed chromosome congression by immunostaining with
antibodies that visualize KTs and mitotic spindles (Figure 3b).
Treatment with SM15 and SM17 signiﬁcantly increased the
frequencies of unaligned, polar KTs, indicative of unattached or
syntelically attached chromosomes (Figure 3b, SM15, Figure 3c).22
These ﬁndings suggest that SMs delay mitotic progression by
interfering with KT–MT attachment, thereby activating spindle
assembly checkpoint. Consistently, KTs of unaligned chromo-
somes in SM15-treated cells accumulated the checkpoint protein
BubR1 (Supplementary Figure 6). To test the nature of KT–MT
interactions in the presence of MT-Hec1-interacting SM15, we took
advantage of a calcium buffer that selectively depolymerizes both
non-KT MTs and unstable KT–MT interactions.23 Incubation with
calcium buffer before ﬁxation demonstrated that interactions
between Hec1 and MTs, visualized by antibody staining, were
maintained in the presence of SM15 (Figure 3d, arrowheads),
indicating that the compound does not act as classical MT
depolymerizing agents, such as nocodazole or colchicine, that
prevent the formation of stable KT–MT interactions. The
occurrence of polar chromosomes in the presence of stable KT–
MT interactions led to the hypothesis that SM15 could inhibit the
correction of syntelic or monotelic KT–MT attachments that
maintain chromosomes close to the spindle poles.22 To test this
hypothesis, we used monastrol (MON), a chemical inhibitor of the
kinesin-5 protein Eg5. As Eg5 activity is required for spindle pole
Figure 2. MT-Hec1-interacting SMs lead to a G2/M phase accumulation and induce apoptosis in HeLa cells. (a) Representative ﬂow cytometric
histograms of cell cycle distribution following 24 h exposure to different concentrations of FB and SM15. X axis=DNA content (linear scale),
Y axis=number of events. (b) Quantitative analysis of the percentage of cells in G2/M phases of the cell cycle after 24 h exposure to FB, SM15,
SM16 and SM17. Data are means± s.e.m. of 2–4 independent experiments. 1 μM nocodazole (NOC) was used as positive control. ***P < 0.001.
(c) Representative ﬂow cytometric histograms of the hypodiploid peak following different exposure times to 10 μM FB or SM15. X axis=DNA
content (log scale), Y axis=number of events. (d) Quantitative analysis of the percentage of hypodiploid cells following different exposure
times to 10 μM FB, SM15, SM16 and SM17. Data are means± s.e.m. of 2–4 independent experiments. (e) Western blotting analysis of PARP
cleavage after different exposure times to 7.5 and 10 μM SM15. Actin is shown as loading control.
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separation at mitosis, MON-induced Eg5 inhibition produces
monopolar spindles with sister KTs syntelically or monotelically
attached to the single spindle pole. Upon MON removal,
monopoles reorganize to form bipolar spindles and incorrect
attachments are corrected (Figure 3e).22,24 In this assay, SM15
strongly inhibited the correction of erroneous attachments as
shown by the persistence of polar chromosomes after release
from MON arrest (Figures 3e and f). Altogether, these ﬁndings
suggest that SM15 inhibits KT–MT error correction possibly by
stabilizing KT–MT interactions.
Live cell imaging
To assess the fate of mitoses with defective KT–MT interactions,
we followed mitotic division by time-lapse microscopy in HeLa
cells (Figure 4). Whereas untreated cells progressed through
mitosis and reattached to the substrate within a time interval of
~ 1 h, cells entering mitosis in the presence of SM15 experienced
a marked lengthening of mitosis with a mean mitotic time
exceeding 11 h (Figures 4a and b; Supplementary material,
video 1 and 2). All mitotic cells died during mitosis or shortly
after reattachment to the substrate. Visual inspection of the
videos demonstrated that cell death occurred in prometaphase
or intervened after chromosome segregation, or nuclear
blebbing and cell death occurred after cell re-adhesion
(Figures 4a and c). Visualization of H2B-GFP and α-tubulin-RFP
ﬂuorescence in U2OS osteosarcoma cells allowed us to follow
the dynamics of chromosome congression and mitotic spindle
organization in untreated live cells (Figure 4d, Supplementary
material, video 3) or cells treated with SM15 (Figure 4e,
Supplementary material, video 4). Consistent with our immuno-
ﬂuorescence results, chromosomes did not properly congress to
the metaphase plate in treated cells. Furthermore, prometa-
phase arrest was followed by plasma membrane movements,
DNA collapse and cell death (Figure 4e). The recorded death
phenotypes recapitulate the morphological signs of mitotic
catastrophe, a speciﬁc type of apoptosis elicited by mitotic
disruption.25,26 Hence, MT-Hec1-interacting compounds can
promote cell death via mitotic catastrophe. Surprisingly, we
also detected massive cell death starting from interphase in
both HeLa (Figures 4f and h) and U2OS cells (data not shown).
This occurred through extensive membrane blebbing (Figure 4f,
blebbing) or membrane blebbing preceded by cell contraction
(Figure 4f, rounding up) or formation of large vacuoles
(Figure 4f, vacuoles, Supplementary material, video 5), with a
time interval from the initial signs of cell contraction to the end
of cell movements ranging from 5 to 9 h (Figure 4g). Altogether,
these results show that SM15 induces cell death in tumor cell
lines both by mitotic catastrophe and by apoptotic cell death
directly from interphase.
Figure 3. MT-Hec1-interacting SMs disrupt mitotic division in HeLa cells. (a) Quantitative analysis of anaphase percentage after 3 h treatment
with FB, SM15, SM16 and SM17. Data are means± s.e.m. obtained by scoring 240 mitoses per condition in three independent experiments.
(b) Representative images of untreated cells showing chromosomes aligned to the metaphase plate and SM15-treated cells with
chromosomes remaining at the spindle poles, as identiﬁed by KT signals at spindle poles (arrows). Mitotic spindles (red) and KTs (green) are
visualized by α-tubulin and CREST antibodies. Chromosomes are identiﬁed by DAPI staining (blue). (c) Quantitative analysis of prometaphases
(PM) showing polar chromosomes following 3 h exposure to FB, SM15, SM16 and SM17. Data are means± s.e.m. obtained by scoring 240 PM
per condition in three independent experiments. (d) Representative images of calcium-resistant MTs in HeLa cells treated with DMSO or 10 μM
SM15 for 3 h. MTs (green) and KTs (red) are visualized by immunostaining α-tubulin and Hec1. Chromosomes are identiﬁed by DAPI staining
(blue). Images in the ﬁrst column are maximum intensity projections of a Z series of optical sections at 0.5 μm interval. In the second and third
column single optical sections of MTs and KTs are presented to better visualize KT–MT attachments (arrowheads). (e) Representative images of
MON-induced monopolar spindles (monastrol), fully aligned bipolar spindles in control cells (DMSO) or bipolar spindles with polar
chromosomes in SM15-treated cells (SM15) at the end of the recovery time from MON arrest (45 min release). Cells were incubated with
100 μM MON for 4 h and then released in 10 μM MG-132-containing medium with or without 10 μM SM15. (f) Quantitative analysis of
prometaphases/metaphases (PM/M) showing aligned chromosomes or polar chromosomes after 45 min recovery time from MON arrest in
DMSO-treated and SM15-treated cells. Data are means± s.e.m. obtained by scoring ⩾ 100 PM/M per condition in two independent
experiments. *Po0.05. Bars= 5 μm.
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Stabilization o f MTs
The unexpected ﬁnding that SM15 caused a strong induction of
cell death from interphase prompted us to investigate the
consequences of SM15 treatment on the MT network as a whole.
To this aim, we induced MT depolymerization by incubating cells
on ice (Figure 5a) and assessed the resistance of SM-treated
cells to this procedure. Our data show that spindle MTs in control
cells progressively depolymerized with increasing ice incubation
times (Figure 5a) so that 480% of dimethylsulfoxide (DMSO)-
treated mitoses were fully depolymerized after 30min on ice
(Figure 5b). At opposite, spindle MTs in SM15-treated cells were
resistant to MT depolymerization so that only half of the cells were
fully depolymerized at the same time point (Figure 5b). A longer
cold exposure (3 h) was then performed to depolymerize interphase
MTs that are characterized by a lower dynamic instability.27 In line
with data on mitotic cells, the depolymerization of the cytoplasmic
MT network caused by the low temperature in DMSO-treated cells
was recovered in cells treated with SM15 (Figures 5c and d).
Altogether, these ﬁndings demonstrate that both mitotic and
interphase MTs are stabilized by SM15.
Studies on tumor growth in vivo
Next, we investigated the in vivo efﬁcacy of SM15. To this
purpose, established HeLa xenografts in nude mice were treated
with SM15 starting from tumor palpability. As reported in
Figure 6a, in vivo experiments conﬁrmed in vitro results on HeLa
cells. SM15-treated animals showed a signiﬁcant inhibition
of tumor growth starting from day 21 up to the sacriﬁce of
the mice at day 25. Interestingly, apoptosis was conﬁrmed as the
death pathway activated by SM15, as determined by the
enhanced poly ADP-ribose polymerase and caspase 3 cleavage
Figure 4. Apoptotic cell death intervenes from mitosis and interphase after treatment with MT-Hec1-interacting SM15. (a) Still images of an
untreated HeLa cell (DMSO) or a SM15- treated HeLa cell (SM15) recorded by time-lapse microscopy under differential interference contrast
(DIC). Time is given in h:min. Cells enter mitosis at time 00.00. (b) Box-plots with whiskers showing minimum and maximum values of the time
spent in mitosis. (c) Quantitative analysis of cell death phenotypes of mitotic HeLa cells recorded as in a. Data are means± s.e.m. of two
experiments. DMSO N= 50; SM15 N= 28. *** Po0.001 comparing the mean value for death in telophase in control vs SM15-treated samples.
(d) An untreated H2B-GFP and α-tubulin-RFP expressing U2OS cell recorded by time-lapse microscopy under ﬂuorescence and phase contrast.
Chromosome congression and spindle formation are visualized by H2B-GFP and α-tubulin-RFP. (e) An H2B-GFP and α-tubulin-RFP expressing
U2OS cell treated with SM15 and recorded as in d. Chromosomes persist scattered at the poles (01:00) and then collapse (05:05) until DNA
diffuses from the cell when the death process is completed (08:45). (f) Still images of interphase HeLa cells recorded as in (a) undergoing
apoptotic cell death after treatment with SM15. Cells round up and partially detach from the substrate at time 00.00. (g) Box-plots with
whiskers showing minimum and maximum values of the time spent to complete the death process in HeLa cells. ***Po0.001 comparing
mean time in rounding up vs blebbing samples. (h) Quantitative analysis of cell death phenotypes in interphase HeLa cells. DMSO N= 12;
SM15 N= 93. ***Po0.001 comparing the mean value for blebbing in control vs SM15-treated samples. Bars= 5 μm.
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in tumor protein lysates (Figures 6b and c) and by TUNEL assay
(Figure 6d). Indeed, an increase of about two fold in the number
of TUNEL positive cells/ﬁeld was observed in treated xenografts
(6.6 ± 1.2 vs 10.2 ± 1.4). Finally, SM15 did not produce any
adverse health effects on mice, as monitored by diet consump-
tion, body-weight loss, postural and behavioral changes.
Altogether, these ﬁndings represent a clear proof of principle
that MT-Hec1-interacting SM15 can exert anti-tumor activity.
Molecular dynamics simulation
To gain insights into the molecular mechanism mediating the
interaction of SM15 with its targets, we investigated the
modiﬁcation exerted by SM15 on MTs and KT–MT attachments
at the molecular level by carrying out a molecular dynamics (MD)
simulation of the tubulin dimer–Hec1 complex in the presence of
SM15. The predicted binding mode of SM15 is illustrated in
Figure 7a and shows that the molecule occupies the selected
binding area between the two tubulin subunits, interacting with
the surrounding residues (for example, Asp163, Trp407 and
Glu411) and placing the indole-bromophenyl–propenone group
deep in the pocket. This best binding pose obtained for SM15
after docking at the isolated tubulin dimer interface was used as
starting point for the simulation. After 35 ns of simulation, part of
the compound gradually moved from the initial position on the
pocket between the α- and β-tubulin interface toward the Hec1
protein. After 45 ns, SM15 reached a binding conformation,
inserted between the two tubulin subunits and Hec1, that was
maintained until the end of the simulation. Particularly, the
piperidine ring moved toward Hec1 inserting itself in a small
hydrophobic pocket formed by Val122, Leu126, Phe147 and
Tyr170. The rest of the molecule, especially the bromophenyl–
propenone part, remained between the two tubulin subunits,
maintaining some interactions with the tubulin dimer (Figure 7b).
Altogether, these data indicate that the molecule can bind the MT
surface independently from Hec1 and acts as a stabilizer of both
the MT and the MT–KT interaction.
DISCUSSION
KTs represent an interesting anticancer drug target owing to their
fundamental role in mitosis. In an effort to ﬁnd SMs acting at KTs
we carried out a virtual screening study targeting the interaction
surface area between Hec1 and MTs. A new interesting and well-
deﬁned pocket at the interface between the two tubulin subunits
was identiﬁed and its vicinity to the tubulin-Hec1 contact area
made this pocket a potential target for our in silico studies. The
virtual screening process led to the identiﬁcation of two new SMs
(SM15 and SM17) with elevated anti-proliferative, pro-apoptotic
and anti-mitotic activities. The molecular interaction of SM15 to
MTs had been further clariﬁed. Docking studies on SM15 showed
that the compound could potentially bind at the tubulin
dimerization interface and could interact with amino acids from
both α- and β-tubulin, acting as potential bridge (stabilizer)
between the two tubulin subunits. These ﬁndings are in line with
the SPR results, in which SM15 was able to bind directly and with
high afﬁnity to MTs and (to a lesser extent) to tubulin. Our results
also show that SM15 promotes chromosome mis-segregation by
inhibiting the correction of faulty KT–MT attachments through the
stabilization of the KT–MT interaction. MD simulation studies
showed how SM15, after potentially binding at the tubulin dimer
interface, could interact with Hec1 forming a potential bridge
between Hec1 and tubulin, thereby stabilizing the KT–MT
interaction. Furthermore, the molecular modeling suggests that
SM15 can interact with tubulin also in the absence of Hec1,
stabilizing MTs and does not affect the independent binding of
Hec1 to tubulin. Live cell imaging demonstrates that cell death
intervenes both from mitosis and from interphase and that this
phenotype is associated with hyper-stable mitotic and interphase
MTs. Overall, these experimental data, supported by the molecular
modeling results, suggest that SM15 acts speciﬁcally toward the
MTs, stabilizing MT dynamics in mitosis and interphase. Thus, we
can conclude that the virtual screening study designed to identify
novel molecules able to inhibit/modify the MT–Hec1 interaction
led to the identiﬁcation of a novel tubulin stabilizer drug. The
tested molecule has the unique characteristic of interacting with
the external surface of the MT cylinder, at odds with known MT
Figure 5. Mitotic and interphase MTs are stabilized by SM15
treatment. (a) Representative images of MT depolymerization during
incubation on ice. After short incubation times on ice, non-KT MTs
depolymerize leaving behind only K-ﬁbers, that is, the bundle of MTs
attached to KTs; for longer times on ice also K-ﬁbers depolymerize
leading to fully depolymerized spindles (third and forth image in the
row). MTs (red) and spindle poles (green) are visualized by α-tubulin
and γ-tubulin immunostaining. (b) Quantitative analysis of the
percentage of fully depolymerized spindles in cells exposed to
DMSO or 10 μM SM15 for 3 h prior and during 10, 20 or 30 min
incubation on ice. The graph shows means± s.e.m. by scoring 240
mitoses per condition in three independent experiments. (c)
Representative images of the interphase MT network in the different
treatment conditions as visualized by α-tubulin immunostaining. (d)
Quantitative analysis of interphase MT depolymerization in cells
exposed to 1% DMSO, SM15, SM16 (10 μM) or 0.1 μM taxol (TAX) for
3 h prior and during 3 h of incubation on ice. The graph shows
means of α-tubulin ﬂuorescence intensity± s.e.m. (in arbitrary units)
by measuring 20 cells per condition from two independent
experiments. α-tubulin ﬂuorescence intensity in untreated cells is
set as 1. *Po0.05.
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stabilizing agents that interact at speciﬁc locations within the MT
lumen.28 Apart from a recent work that evidenced a binding site
for paclitaxel at the outer MT surface before the drug reaches the
internal lumen site,29 several interaction sites have been mapped
for MT stabilizing agents, but all reside in the internal lumen.28 The
interaction of SM15 on external surface of the MTs could provide
an explanation for its effects outside mitosis, since its binding to
MTs could efﬁciently affect already assembled interphase MTs.
This conclusion is supported by the modeling studies that
delineate the binding site of SM15 on the external interface
between the tubulin chains. In addition, SM15 could stabilize the
KT–MT interaction by bridging the tubulin dimer and Hec1.
In conclusion, starting from a rational approach, we identiﬁed a
new compound, SM15, which present a dual mechanism: MT
stabilizer agent and stabilizer of KT–MT interactions. Both these
properties give to SM15 the potentialities to emerge as a novel
powerful anticancer agent, promoting chromosome mis-
segregation by stabilizing faulty KT–MT attachments. In addition
to this mechanism, stabilization of MT dynamics in interphase by
SM15 may represent an important feature of its anticancer activity,
by promoting massive apoptosis of malignant cells, independently
of mitosis.
MATERIALS AND METHODS
Molecular modeling
All molecular docking studies were performed on a Viglen Genie Intel Core
i7-3770 vPro CPU@ 3.40 GHz× 8 running Ubuntu 14.04. Molecular
Operating Environment (MOE) 2015.1030 and Maestro (Schrödinger
Release 2016-1)31 were used as modeling softwares. The cryo-electron
microscopy density map and the Ndc80 docking model coordinates were
downloaded from the PDB data bank (PDB code 3IZ0).16 The tubulin dimer
(chains A and B) together with the Ndc80-SPC25 chimera protein (Hec1-
containing chain C) were extracted from the protein model. The complex
was preprocessed using the Schrödinger Protein Preparation Wizard by
assigning bond orders, adding hydrogens and performing a restrained
energy minimization of the added hydrogens using the OPLS_2005 force
ﬁeld. The library of commercially available compounds was downloaded
from SPECS website (www.specs.net) in a sdf format and prepared using
the Maestro LigPrep tool by energy minimizing the structures (OPLS_2005
force ﬁeld), generating possible ionization states at pH 7±2, generating
tautomers and low-energy ring conformers. After removing the Ndc80-
SPC25 chimera protein, a 12Å docking grid (inner-box 10Å and outer-box
22Å) was prepared using as centroid the area deﬁned by Glu411 and
Trp407 (α-tubulin chain) and Asp199, Ile165, Asp163 and Arg253 (β-tubulin
chain) in the isolated tubulin dimer structure. Molecular docking of the
prepared SPECS library was performed using Glide HTVS. The best 5000
ranked compounds obtained were docked using the more accurate Glide
SP precision setting 1 as output pose per input structure. The output poses
were then ﬁnally docked with Glide XP scoring function and the output
database saved as mol2 ﬁle. The best 500 compounds according to the
Glide XP results were visually inspected for their ability to bind the active
site and 15 derivatives were selected and purchased.
MD simulations were performed on Supermicro Intel Xeon CPU
ES-46200 @ 2.20 GHz × 12 running Ubuntu 14.04 using the Desmond
package for MD simulation: OPLS-AA force ﬁeld in explicit solvent,
employing the TIP3 water model was used. The initial coordinates for the
MD simulation were taken from the best docking result for compound
SM15 at the tubulin dimer interface. A cubic water box was used for the
solvation of the system, ensuring a buffer distance of ~ 10 Å between each
box side and the complex atoms. The system was neutralized adding 27
sodium counter ions. The system was minimized and pre-equilibrated
using the default relaxation routine implemented in Desmond. A 100 ns
MD simulation was performed, during which the equations of motion were
integrated using a 2 fs time step in the NPT ensemble, with temperature
(300 K) and pressure (1atm) constant. All other parameters were set using
the Desmond default values. Data were collected every 40ps (energy) and
every 160 ps (trajectory). Visualization of protein-ligand complex and MD
trajectory analysis were carried out using Maestro. The MD simulation was
performed in presence of Hec1 protein isolated from the Ndc80-SPC25
chimera protein (124 amino acids from Met79 to Ser202).
Figure 6. MT-Hec1-interacting SM15 inhibits HeLa tumor growth in vivo. (a) Tumor growth curves in mice with or without intraperitoneal
injection of SM15 (10 mg/kg) for ﬁve consecutive days for three weeks starting from tumor palpability. (b) Western blotting analysis of cleaved
PARP and cleaved caspase 3 in protein lysates from tumors excided at sacriﬁce. HSP is shown as loading control. (c) Cleaved PARP/HSP ratio
and cleaved caspase 3/HSP ratio from the densitometric analysis of western blots in b. Each scatter plot presents individual values of control
and SM15-treated animals. (d) Representative images of TUNEL staining in histological sections from tumors excided at sacriﬁce. Bar= 20 μm.
*Po0.05 by non-parametric Mann–Whitney test.
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Cell culture and viability assays
HeLa cells, MDA-MB-231 breast cancer cells (originally purchased from
ATCC) and U2OS cells stably expressing H2B-GFP and RFP-α-tubulin (a kind
gift of L Lanzetti, Institute for Cancer Research at Candiolo, Italy) were
grown in DMEM medium supplemented with 10% fetal bovine serum, 1%
L-glutamine and antibiotics. MCF10A cells were cultured in DMEM/F12
medium supplemented with 5% horse serum, 10 μg/ml insulin, 0.5 μg/ml
hydrocortisone and 20 ng/ml epidermal growth factor. Cells were grown at
37 °C in a humidiﬁed atmosphere containing 5% CO2 and routinely tested
for mycoplasm contamination. All SMs were stored as 10 mM stock
Figure 7. SM15 binding conformation after MD simulation. (a) Predicted binding mode of SM15 (carbon atoms in emerald) in the selected
binding area between the two tubulin subunits. The molecule is interacting with the surrounding residues (for example Asp163, Trp407 and
Glu411) placing the indole-bromophenyl–propenone group deep in the pocket. (b) After 100 ns MD simulation, the piperidine ring of SM15
moved toward Hec1 inserting itself in a small hydrophobic pocket within the calponin homology domain formed by Val122, Leu126, Phe147
and Tyr170 (carbon atoms in gold). The rest of the molecule, especially the bromophenyl–propenone part, remained between the two tubulin
subunits. Interactions of SM15 with Hec1 and β-tubulin are represented as dashed red and green lines, respectively.
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solutions in DMSO at − 20 °C and added after serial dilutions in order not to
exceed 1% DMSO in medium. A total of 6 × 105 HeLa cells were seeded in
25 cm2 ﬂasks and exposed 24 h later to different concentrations of SMs.
Cells were harvested 24 h later to obtain IC50 values or after 24, 48, 72 h
from SM addition in time course experiments. Cell counting was performed
by a Z1 Coulter Counter (Beckman Coulter, Brea, CA, USA) and cell viability
was assessed by trypan blue exclusion. Cell cycle progression and
apoptosis were evaluated on the same samples by ﬂow cytometry on an
Epics XL apparatus (Beckman Coulter) using propidium iodide staining. Ten
thousand events were collected from each sample.
SPR experiments
SPR experiments were carried out using a SensiQ Pioneer system. The
sensor chip (COOH5) was activated chemically by a 35 μl injection of a 1:1
mixture of N-ethyl-N’-3-(diethylaminopropyl)carbodiimide (200 mM) and N-
hydroxysuccinimide (50 mM) at a ﬂow rate of 5 μl/min. Ligands, that is,
tubulin (3900 RU) and assembled MTs (6050 RU), were immobilized on
activated sensor chips via amine coupling as previously reported:32
immobilizations were carried out in 10 mM sodium acetate at pH 4.0; ﬂow
cell Fc2 was left empty and used as a reference surface. The remaining
ester groups were blocked by injecting 1 M ethanolamine hydrochloride
(35 μl). SM15 was dissolved in DMSO to a ﬁnal concentration of 10 mM, and
then diluted 1:50 in buffer A (10 mM Hepes pH 7.4, 150 mM NaCl+0.05%
surfactant P20+2 mM MgCl2). Further dilutions of SM15 were carried out in
running buffer (buffer A+2% DMSO); each sample was injected in duplicate
on the sensor chip for 240 s (contact time) followed by a dissociation of
1000 s, at a ﬂow rate of 30 μl/min. Regeneration procedures included two
long (1000 s and 300 s) injections of buffer, separated by a 30 s injection of
10 mM glycine pH 1.5. The sensorgrams were analyzed using the SensiQ
Qdat program.
Western blotting
Western blot experiments were performed as previously described.33 In
brief, cells were lysed in RIPA buffer and 40 μg of total proteins were
resolved in 4–12% gradient gels by SDS-PAGE. Proteins were transferred
onto nitrocellulose membranes and incubated with rabbit anti-poly ADP-
ribose polymerase (11835238001, Roche Diagnostics GmbH, Mannheim,
DE, USA), active caspase 3 (559565, BD Biosciences, St Jose, CA, USA) and
goat anti-actin (Sc1616, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
antibodies. Protein lysates from tumors were probed with poly ADP-ribose
polymerase cleavage antibody (AB3565, Millipore, Billerica, MA, USA) and
HSP72/73 antibody (HSP01, Millipore). The membranes were subsequently
probed with the appropriate horseradish peroxidase-conjugated second-
ary antibodies (Santa Cruz Biotechnology) and antigens on the membrane
were revealed by enhanced chemiluminescence (RPN2209, GE Healthcare,
Little Chalfont, UK).
Immunoﬂuorescence microscopy and analysis
Cells were rinsed in PHEM (60 mM PIPES, 25 mM Hepes, 10 mM EGTA, 2 mM
MgCl2) buffer, ﬁxed in 3.7% formaldehyde in PHEM, permeabilized in 0.3%
Triton X-100 and post-ﬁxed in cold methanol. Coverslips were processed
for immunoﬂuorescence using the following antibodies: anti-α- or γ-
tubulin (T6199, T3559, Sigma-Aldrich, St Louis, MO, USA), anti-KT serum
(CREST, Antibodies Inc., Davis, CA, USA), anti-Hec1 (GTX70268, Genetex,
Irvine, CA, USA). DNA was counterstained with 0.05 μg/ml 4,6-diamidino-2-
phenylindole (DAPI, Sigma-Aldrich). Preparations were examined under an
Olympus AX70 microscope using a 100× /1.35 NA objective. Images were
acquired using a TCH-1.4ICE camera (Tucsen, Fujian, China) controlled by
ISCapture and processed by Photoshop CS. Measurements of ﬂuorescence
intensity over the cell area were obtained from images acquired under
identical exposure settings using NIH ImageJ 1.3 software.
Live cell microscopy
A total of 3 × 104 HeLa or U2OS cells/well were seeded in four-well
microslides (80426, Ibidi, Martinsried, DE) and time-lapse observation
started 24 h later, when 5 μM SM15 was added to the medium. Cells were
recorded under an Eclipse Ti inverted microscope (Nikon, Tokyo, Japan),
using a Plan Fluor 40× /0.6 NA or 60× /0.7 NA objective (Nikon) for DIC and
ﬂuorescence, respectively; during the whole observation cells were kept in
a microscope stage incubator (Basic WJ, Okolab, Naples, Italy) at 37 °C and
5% CO2. Images were acquired over 24 h at 3 min for phase contrast or DIC
and 30 min for ﬂuorescence. Videos and still images were processed using
NIS-Elements AR 3.2.
Tumor xenografts and TUNEL in nude mice
HeLa cells in exponential growth phase were harvested from the culture,
washed and resuspended in PBS and 4× 106 cells were subcutaneously
injected into 6–8-week-old male CD-1 nude (nu/nu) mice. After the
appearance of palpable tumors, animals were allocated into treatment
groups (n=8/group) on the basis of their tumor volume to obtain two
similar groups, that subsequently received either no treatment or SM15.
Two different experiments were performed. Animals were intraperitoneally
treated with SM15 (10 mg/kg) sonicated and dissolved in 1% carbox-
ymethyl cellulose for ﬁve consecutive days for three weeks starting from
tumor palpability. Diet consumption, body-weight loss, and postural and
behavioral changes were monitored daily. Animals were sacriﬁced 25 days
after cell injection, tumors were removed and proteins extracted. We
applied the Shapiro–Wilk test to evaluate the normality of the weight
distribution of the treated mice and controls. Both distributions, at the two
time points, were not normally distributed. Thus, in order to explore
potential differences between the two treatment groups we used the non-
parametric Mann–Whitney test. Results were considered to be statistically
signiﬁcant if Po0.05. Mice were purchased from Charles River Laboratories
(Calco, Italy). All procedures involving animals and their care were
authorized and certiﬁed by D.lgs 26/2014 (816/2015-PR del 11/08/2015)
of the Italian Health Ministry. The immunohistochemical detection of
apoptosis was performed by TUNEL assay using a commercial kit (In Situ
Cell Death Detection Kit, POD, Roche). The assay was performed according
to the manufacturer's instructions. For each tumor, three different 5 μm
frozen sections were analyzed and examined by light microscopy. Sections
were scanned at × 200 magniﬁcation. Apoptosis of tumor cells was
counted in four high-power ﬁelds (×400 magniﬁcation) per section.
Statistical analysis
All data are presented as mean± s.e.m. Signiﬁcance of differences between
experimental variables was determined by unpaired two-tailed Student’s t-
test unless otherwise stated. A P-value of 40.05 was considered
signiﬁcant. Statistical analyses were performed using the GraphPad Prism
program. The sample sizes were determined by power analysis, based on
variation shown in our previous experiments.12 No data were excluded
from any analysis. Evaluation of immunoﬂuorescence and TUNEL samples
was performed independently and in blinded manner by two investigators.
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